Ubisol-Q10 (a Nanomicellar Water-Soluble Formulation of CoQ10) Treatment Inhibits Alzheimer-Type Behavioral and Pathological Symptoms in a Double Transgenic Mouse (TgAPEswe, PSEN1dE9) Model of Alzheimer’s Disease
The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
Alzheimer's disease (AD) is one of the most common neurodegenerative pathologies for which there are no effective therapies to halt disease progression. Given the increase in the incidence of this disorder, there is an urgent need for pharmacological intervention. Unfortunately, recent clinical trials produced disappointing results. Molecular mechanisms of AD are converging on the notion that mitochondrial dysfunction, oxidative stress, and accumulation of dysfunctional proteins are involved in AD pathology. Previously, we have shown that a water-soluble formulation of Coenzyme Q10 (Ubisol-Q10), an integral part of the electron transport chain, stabilizes mitochondria and prevents neuronal cell death caused by neurotoxins or oxidative stress both in vitro and in vivo. In this study, we evaluated the neuroprotective effects of Ubisol-Q10 treatment in double transgenic AD mice. In the present study, we report that providing Ubisol-Q10 in drinking water (at a dose of ∼6 mg/kg/day) reduced circulating amyloid-β (Aβ) peptide, improved long term memory, preserved working spatial memory, and drastically inhibited Aβ plaque formation in 18-month-old transgenic mice compared to an untreated transgenic group. Thus Ubisol-Q10 supplementation has the potential to inhibit the progression of neurodegeneration, leading to a better quality of life for humans suffering with AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123
López-Otín, C., Blasco, M. A., Partridge, L., Serrano, M., & Kroemer, G. (2013) · Cell · doi:10.1016/j.cell.2013.05.039 · Cited by 14,982
Candidate gene for the chromosome 1 familial Alzheimer’s disease locus
Levy-Lahad, E., Wasco, W., Poorkaj, P., Romano, D. M., Oshima, J., Pettingell, W. H., Yu, C.-E., Jondro, P. D., Schmidt, S. D., Wang, K., et al. (1995) · Science · doi:10.1126/science.7638622 · Cited by 2,577 · cited 1×
“-secretase enzyme that cleaves amyloid-(cid:2) protein precursor (A (cid:2) PP) via the (cid:2) -secretase pathway to give rise to A (cid:2) [4–6].”
Holcomb, L., Gordon, M. N., McGowan, E., Yu, X., Benkovic, S., Jantzen, P., Wright, K., Saad, I., Mueller, R., Morgan, D., et al. (1998) · Nature Medicine · doi:10.1038/nm0198-097 · Cited by 1,386
Billings, L. M., Oddo, S., Green, K. N., McGaugh, J. L., & LaFerla, F. M. (2005) · Neuron · doi:10.1016/j.neuron.2005.01.040 · Cited by 1,294
A mutation in the Amyloid Precursor Protein Associated with Hereditary Alzheimer's Disease
Murrell, J., Farlow, M., Ghetti, B., & Benson, M. D. (1991) · Science · doi:10.1126/science.1925564 · Cited by 1,127
Spatial memory, recognition memory, and the hippocampus
Broadbent, N. J., Squire, L. R., & Clark, R. E. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0406344101 · Cited by 985
Yao, J., Irwin, R. W., Zhao, L., Nilsen, J., Hamilton, R. T., & Brinton, R. D. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0903563106 · Cited by 940
Inflammatory processes in Alzheimer's disease
Heneka, M. T., & O'Banion, M. K. (2007) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2006.11.017 · Cited by 782
Space in the brain: How the hippocampal formation supports spatial cognition
Hartley, T., Lever, C., Burgess, N., & O'Keefe, J. (2014) · Philosophical Transactions of the Royal Society B: Biological Sciences · doi:10.1098/rstb.2012.0510 · Cited by 495 · cited 1×
“…such spatial memory deficits along with our observations of changes in the hippocampus in untreated transgenic mice is consistent with earlier extensive research supporting and extending O’Keefe and Nadel’s (1978) original idea about the involvement of this structure in spatial cognition [46–48].”
Spatial cognitive maps in animals: New hypotheses on their structure and neural mechanisms.
Poucet, B. (1993) · Psychological Review · doi:10.1037/0033-295x.100.2.163 · Cited by 434
Huang, Y., Liu, X. Q., Wyss-Coray, T., Brecht, W. J., Sanan, D. A., & Mahley, R. W. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.151254698 · Cited by 392
He, P., Zhong, Z., Lindholm, K., Berning, L., Lee, W., Lemere, C., Staufenbiel, M., Li, R., & Shen, Y. (2007) · The Journal of Cell Biology · doi:10.1083/jcb.200705042 · Cited by 390
A randomized, placebo-controlled trial of coenzyme Q 10 and remacemide in Huntington’s disease
The Huntington Study Group (2001) · Neurology · doi:10.1212/wnl.57.3.397 · Cited by 312
Cerbai, F., Lana, D., Nosi, D., Petkova-Kirova, P., Zecchi, S., Brothers, H. M., Wenk, G. L., & Giovannini, M. G. (2012) · PLoS ONE · doi:10.1371/journal.pone.0045250 · Cited by 251
Targeting mitochondrial dysfunction and neurodegeneration by means of coenzyme Q10 and its analogues
Orsucci, D., Mancuso, M., Ienco, E. C., LoGerfo, A., & Siciliano, G. (2011) · Current Medicinal Chemistry · doi:10.2174/092986711796957257 · Cited by 97
Sikorska, M., Lanthier, P., Miller, H., Beyers, M., Sodja, C., Zurakowski, B., Gangaraju, S., Pandey, S., & Sandhu, J. K. (2014) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2014.03.032 · Cited by 70
Self-citationRhein, V., & Eckert, A. (2007) · Archives of Physiology and Biochemistry · doi:10.1080/13813450701572288 · Cited by 56 · cited 1×
“…AD are loss of neurons in the hippocampal region leading to learning and memory impairments, aggregation and deposition of amyloid fibrils forming neuritic plaques outside neurons, and accumulation of hyperphosphorylated tau that form neurofibrillary tangles (NFT) inside the nerve cell bodies [2, 3].”
Ma, D., Stokes, K., Mahngar, K., Domazet-Damjanov, D., Sikorska, M., & Pandey, S. (2014) · Mitochondrion · doi:10.1016/j.mito.2014.07.004 · Cited by 39
Self-citation
Cited by
Oxidant/Antioxidant Imbalance in Alzheimer’s Disease: Therapeutic and Diagnostic Prospects
Wojsiat, J., Zoltowska, K. M., Laskowska-Kaszub, K., & Wojda, U. (2018) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2018/6435861 · Cited by 221
Gutierrez-Mariscal, F. M., Arenas-de Larriva, A. P., Limia-Perez, L., Romero-Cabrera, J. L., Yubero-Serrano, E. M., & López-Miranda, J. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21217870 · Cited by 190
“Behind these physiological and structure presentations of the disease, there are a number of molecular mechanisms described as being associated with AD, such as increased oxidative stress [98], mitochondrial dysfunction, impaired autophagy activity, and a resulting accumulation of defective proteins/organelles [99].”
BackgroundResultPeng, Y., Gao, P., Shi, L., Chen, L., Liu, J., & Long, J. (2020) · Antioxidants & Redox Signaling · doi:10.1089/ars.2019.7763 · Cited by 110
Metadata
- Authors
- Muthukumaran, K., Kanwar, A., Vegh, C., Marginean, A., Elliott, A., Guilbeault, N., Badour, A., Sikorska, M., Cohen, J., & Pandey, S.
- Venue
- Journal of Alzheimer's Disease
- Publisher
- SAGE Publications
- Published
- 2017-11-28
- Volume
- 61
- Issue
- 1
- Pages
- 221-236
- ISSN
- 1387-2877 (ISSN-L)
- 1875-8908
- OpenAlex
- W2770368300
- Cited by
- 59
- References
- 19
- FWCI
- 1.89
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.